On June 30, 2025, Edgewise Therapeutics (EWTX, Financial) received new analyst coverage from HC Wainwright & Co., as announced by analyst Joseph Pantginis. The analyst has initiated a "Buy" rating for the stock.
The analyst also announced a price target of USD 42.00 for Edgewise Therapeutics (EWTX, Financial). This initiation provides a fresh perspective on the biotechnology company, which focuses on creating innovative medical therapies.
This new coverage marks a significant event for Edgewise Therapeutics (EWTX, Financial), as it could influence investor perceptions and market activity. Investors may watch for further developments based on this analyst's forecast and recommendations.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Edgewise Therapeutics Inc (EWTX, Financial) is $39.44 with a high estimate of $51.00 and a low estimate of $14.00. The average target implies an upside of 199.96% from the current price of $13.15. More detailed estimate data can be found on the Edgewise Therapeutics Inc (EWTX) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Edgewise Therapeutics Inc's (EWTX, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
